Indian generics slowly moving towards invention model but incentives are scant
In light of the recent headline-making Glivec decision, all eyes are now on the Indian pharmaceutical industry. Amidst all the clamour about whether or not India is anti-patent or if big pharma will look elsewhere to invest, no-one seems to be…
To read more
Register for limited access
Register to receive our weekly newsletter and access two of our subscriber-only articles per month.
Subscribe and start reading now
Subscribe for unlimited access to articles, in-depth analysis and research from the IAM experts.